About Mavenclad

The Mavenclad Dose Calculator is a support tool for healthcare professionals to determine the appropriate weight-based dosing regimen for Mavenclad (Cladribine). Mavenclad is an oral medication approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It works by selectively targeting and reducing the number of certain immune cells (B and T lymphocytes) that are involved in the MS disease process. The treatment is unique in that it is administered in two annual courses, with each course consisting of two short treatment cycles.

Outputs Explained

The calculator provides a comprehensive breakdown of the two-year treatment plan based on the patient's weight:

• Weight Conversion: Displays the patient's weight in both kilograms (kg) and pounds (lbs) for verification.
• Total Tablets: Shows the total number of 10mg tablets required for the complete two-year treatment.
• Dose Per Cycle: Details the specific number of tablets to be administered during each of the four treatment cycles.
• Daily Administration Schedule: Provides a day-by-day plan for each cycle (over 4-5 days), specifying how many tablets the patient should take each day.

How to Use the Calculator

To determine the correct dosing regimen, follow these steps:

1. Enter Patient Weight: Input the patient's current body weight into the designated field.
2. Select Units: Choose the appropriate unit of measurement, either kilograms (kg) or pounds (lbs).
3. Calculate Dose: Click the "Calculate Dose" button to generate the complete, weight-based dosing schedule. The tool will display an error if the weight is outside the recommended range (e.g., below 40 kg).

Dosing Overview

The total cumulative dose of Mavenclad is 3.5 mg per kg of body weight, administered over two years. However, for practical administration, the total number of tablets is determined by pre-defined weight bands, not a direct mg/kg calculation. Each annual course consists of two treatment cycles, separated by approximately one month.

The second treatment course begins 12 months after the start of the first course. The dosing for the second year is identical to the first, following the same weight-based schedule.

Switching Therapies

When switching a patient to Mavenclad from another disease-modifying therapy (DMT), healthcare providers must consider the mechanism of action and potential for additive immunosuppressive effects of the prior treatment. It is crucial to allow for an adequate washout period and to ensure lymphocyte counts meet the required parameters before initiating Mavenclad, as specified in the official prescribing information.

Missed Dose Protocol

If a dose is missed, the patient should not take the missed dose on the following day along with the scheduled dose. Instead, they should consult their healthcare provider for instructions. The treatment period for a cycle may need to be extended. Double doses should never be taken to make up for a missed dose.

Safety Alerts

Important: Mavenclad carries a boxed warning regarding an increased risk of malignancy and teratogenicity. It is contraindicated in patients with an active malignancy, in pregnant women, and in men and women of reproductive potential who do not plan to use effective contraception. Complete blood counts, including lymphocyte counts, must be performed before, during, and after treatment. Treatment should not be initiated in patients with active infections.

Frequently Asked Questions (FAQ)

• Why is Mavenclad not recommended for patients under 40 kg? The clinical trials and dosing recommendations for Mavenclad did not include patients weighing less than 40 kg. Its safety and efficacy have not been established in this population.
• How is the daily tablet schedule determined? Within each treatment cycle, the total number of tablets is administered over 4 or 5 consecutive days. Patients take either one or two tablets per day. The calculator's schedule ensures no more than two tablets are taken on any single day.
• What is the difference between a "course" and a "cycle"? A "treatment course" refers to one year of treatment. Each annual course is divided into two "treatment cycles," which are approximately one month apart. The full treatment consists of two courses over two years.
• Is the total dose always exactly 3.5 mg/kg? No. While the target cumulative dose is 3.5 mg/kg, the actual number of tablets is standardized into weight bands for safety and simplicity. The total administered dose will be close to, but not exactly, 3.5 mg/kg.
• Do I need to take Mavenclad with food? Mavenclad can be taken with or without food. Tablets should be swallowed whole with water and without chewing.
• What happens after the two-year treatment is complete? After completing the two treatment courses in two consecutive years, no further cladribine treatment is required in years 3 and 4. The efficacy has been shown to persist for at least two years after the last dose.
• What if a patient's weight changes significantly between Year 1 and Year 2? The dose for the second course is calculated based on the patient's weight at the start of that course. If a patient's weight has changed enough to move them into a different weight band, the dose for Year 2 may be adjusted accordingly.
• Can a patient receive vaccinations while on Mavenclad? Live or live-attenuated vaccines should not be administered during or after Mavenclad treatment while the patient's lymphocyte counts are below the normal range. Consult the prescribing information for specific guidance on vaccination timing.

References

1. MAVENCLAD® (cladribine) Prescribing Information. U.S. Food and Drug Administration.
2. Mavenclad (cladribine) Summary of Product Characteristics (SmPC). European Medicines Agency.
3. Dosing & Administration for MAVENCLAD. EMD Serono, Inc.
4. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426.

Disclaimer: This information is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical conditions or before making any decisions related to health or treatment. All dosing calculations must be confirmed against the official prescribing information.